These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

994 related items for PubMed ID: 23435861

  • 1. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [Abstract] [Full Text] [Related]

  • 2. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P.
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, Hoch JS, Walker S.
    J Natl Cancer Inst; 2013 Aug 07; 105(15):1078-85. PubMed ID: 23873405
    [Abstract] [Full Text] [Related]

  • 4. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.
    Clin Lymphoma Myeloma Leuk; 2010 Jun 07; 10(3):186-91. PubMed ID: 20511163
    [Abstract] [Full Text] [Related]

  • 5. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS, Leather HL, Nejame C, Meyer C, Wingard JR.
    Cytotherapy; 2002 Jun 07; 4(6):531-8. PubMed ID: 12568989
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.
    Clin Ther; 2009 Jun 07; 31 Pt 2():2388-95. PubMed ID: 20110048
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
    Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.
    Ann Hematol; 2011 Jan 07; 90(1):89-94. PubMed ID: 20706722
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
    Tan Sean P, Chouaid C, Hettler D, Baud M, Hejblum G, Tilleul P.
    Curr Med Res Opin; 2009 Jun 07; 25(6):1455-60. PubMed ID: 19419340
    [Abstract] [Full Text] [Related]

  • 17. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M, Jawniak D, Kotwica K, Wach M, Mańko J, Gorący A, Klimek P, Mazurkiewicz E, Jarosz P, Hus M.
    Transplant Proc; 2014 Oct 07; 46(8):2882-4. PubMed ID: 25380941
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
    Faber E, Pytlík R, Slabý J, Zapletalová J, Kozák T, Raida L, Papajík T, Zikesová E, Maresová I, Hamouzová M, Indrák K, Trnený M.
    Eur J Haematol; 2006 Dec 07; 77(6):493-500. PubMed ID: 17042769
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.
    J Clin Oncol; 2013 Dec 01; 31(34):4283-9. PubMed ID: 24166522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.